Phantom_Eagle
$ARMP
Armata Pharmaceuticals press release (ARMP): Q3 GAAP EPS of -$0.24 beats by $0.32.
Revenue of $3.17M (+173.3% Y/Y) beats by $2.72M.
As of September 30, 2026, Armata held approximately $18.3 million of unrestricted cash and cash equivalents, compared to $8.7 million as of December 31, 2025.
2

:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault38.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault42.jpg)
:format(webp)/https%3A%2F%2Fstaticx-tuner.zacks.com%2Fimages%2Fdefault_article_images%2Fdefault32.jpg)